USPTO serial 79124568
QUANTIPLEX
Reviewed by CopyMark Law Group
Reg. 4405272Status 706Registered
- Filing date
- Status date
- Registration date
- Sep 24, 2013
- Examiner
- DIXON, JENNIFER HAZARD
- Law office
- Historical data usage
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with QUANTIPLEX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Victoria Friedman
Victoria Friedman Dennemeyer & Associates, LLC230 W. Monroe St.Suite 2100CHICAGO, IL 60606Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical, biochemical and biotechnological products for industrial and scientific purposes, namely, [ diagnostic preparations except for human or veterinary medical purposes, namely, nonmedical ] reagents, enzymes and buffer solutions for [ scientific and medical research use for sample preparation, modification and manipulation of cells and for conducting marking, separating, isolating, purifying, duplicating and analyzing biopolymers in the nature of nucleic acids, proteins, macromolecules and biologically active substances, namely, reagents, enzymes and buffer solutions for ] nucleic acid amplification by polymerase chain reaction (PCR) [ ; kits comprising chemicals for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating and analyzing biopolymers in the nature of nucleic acids, proteins, macromolecules and biologically active substances, namely, nucleic acids of biological or biochemical sample material comprising chemicals for reagents, enzymes and buffer solutions for nucleic acid amplification by polymerase chain reaction (PCR) ] | ACTIVE | — |
| 005 | [ Diagnostic preparations for medical purposes; diagnostic preparations for veterinary purposes; diagnostic preparations for humans for medical purposes; preparations for medical and veterinary purposes, namely, diagnostic preparations for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating and analyzing biopolymers in the nature of nucleic acids, proteins, macromolecules and biologically active substances, namely, reagents, enzymes and buffer solutions for nucleic acid amplification by polymerase chain reaction (PCR); chemical, biochemical and biotechnological preparations, namely, reagents, enzymes and buffer solutions for sample preparation, modification and manipulation of cells and for conducting marking, separating, isolating, purifying, duplicating and analyzing biopolymers in the nature of nucleic acids, proteins, macromolecules and biologically active substances for diagnostic medical and clinical use, namely, reagents, enzymes and buffer solutions for nucleic acid amplification by polymerase chain reaction (PCR); ] kits containing [ preparations for medical and veterinary diagnostic purposes, in particular for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating and analyzing biopolymers in the nature of nucleic acids from biological or ] biochemical sample material for nucleic acid amplification by polymerase chain reaction (PCR) | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 3, 2025 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| Apr 14, 2025 | INPS | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Apr 14, 2025 | INPC | INVALIDATION PROCESSED | — |
| Feb 1, 2025 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jun 1, 2024 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Jun 1, 2024 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| May 28, 2024 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| May 13, 2024 | PR71 | POST REGISTRATION ACTION MAILED - SEC.71 | — |
| May 5, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Sep 5, 2023 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Dec 30, 2022 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Sep 24, 2022 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Aug 27, 2019 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| Aug 27, 2019 | C75A | REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| Aug 26, 2019 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jul 31, 2019 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Oct 18, 2018 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 24, 2018 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Dec 29, 2014 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 22, 2014 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jan 25, 2014 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jan 9, 2014 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jan 9, 2014 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Dec 24, 2013 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Sep 24, 2013 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 22, 2013 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jul 12, 2013 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 9, 2013 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 9, 2013 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 19, 2013 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jun 19, 2013 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jun 19, 2013 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 3, 2013 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| May 31, 2013 | ALIE | ASSIGNED TO LIE | — |
| May 16, 2013 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 11, 2013 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 10, 2013 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 10, 2013 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 16, 2013 | RFNP | REFUSAL PROCESSED BY IB | — |
| Mar 25, 2013 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 25, 2013 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 23, 2013 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 22, 2013 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 15, 2013 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 15, 2013 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 11, 2013 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 9, 2013 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |